Neoantigen Cancer Vaccine Market - Industry Dynamics, Market Size, and Opportunity Forecast to 2035

Neoantigen Cancer Vaccine Market: By Platform (mRNA, Peptide, DNA, Dendritic Cell, Viral Vector); Antigen Strategy (Individualized Neoantigen, Shared/Off-the-Shelf Antigen); Indication (Melanoma, Non-Small Cell Lung Cancer, Colorectal, Pancreatic, Renal Cell Carcinoma, Others); Treatment Line (Adjuvant / Minimal Residual Disease, Metastatic); End User (Hospitals & Cancer Centers, Specialty Clinics, Biopharma)—Market Size, Industry Dynamics, Opportunity Analysis and Forecast For 2026–2035

The neoantigen cancer vaccine market is estimated at USD 250.7 million in 2025 and is projected to reach USD 9,027.2 million by 2035, growing at a CAGR of 43.1% over the forecast period 2026–2035. Read More

We Are Trusted By These Great Companies!

• Last Updated: 10-Sep-2026  |  Format:  |  Report ID: AA09261983